Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations.1 passage
• A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.1 passage
• A novel approach indirectly comparing benefit-risk balance across anti-thrombotic therapies in patients with atrial fibrillation.1 passage
• A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation.1 passage
• A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease.1 passage
• A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.1 passage
• Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study.1 passage
• Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion.1 passage
• Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry.1 passage
• Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography-tandem mass spectrometry-based urine analysis.1 passage
• Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease.1 passage
• Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.1 passage
• Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review.1 passage
• Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.1 passage
• Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations.1 passage
• All about clinical trial course: one of the masterpieces of the European Society of Cardiology-Working Group on Cardiovascular Pharmacotherapy educational programme.1 passage
• All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease.1 passage
• An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.1 passage
• An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis-results from 19 countries.1 passage
• An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS).1 passage
• Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?1 passage
• Anti-thrombotic strategies in elderly patients receiving platelet inhibitors.1 passage
• Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of > 20000 patients.1 passage
• Antiplatelet Therapy in Patients with Atrial Fibrillation: A Systematic Review and Metaanalysis of Randomized Trials.1 passage
• Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.1 passage
• Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention.1 passage
• Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases.1 passage
• Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI).1 passage
• Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis.1 passage
• Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE.1 passage
• Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction: a retrospective analysis of nationwide registry data.1 passage
• Apixaban versus Warfarin in Patients with Left Ventricular Thrombus, A Prospective Multicenter Randomized Clinical Trial.1 passage
• Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond.1 passage
• Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis.1 passage
• Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach.1 passage
• Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs.1 passage
• Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.1 passage
• Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.1 passage
• Association between renin-angiotensin system inhibitors and COVID-19 complications.1 passage
• Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs.1 passage
• Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality.1 passage
• Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review.1 passage
• Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.1 passage
• Cardiac and Cardiometabolic Phenotyping of Trastuzumab-Mediated Cardiotoxicity: a Secondary Analysis of the MANTICORE trial.1 passage
• Cardio-Renal Benefits of SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Clinical Evidence.1 passage
• Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.1 passage
• Cardiovascular Outcomes with GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Patients with Type 2 Diabetes.1 passage
• Cardiovascular pharmacotherapy: a new ESC Handbook comprehensively addresses pharmacological treatment issues for patients with cardiovascular disease.1 passage
• Cardiovascular risks associated with calcium supplementation in patients with osteoporosis: a nationwide cohort study.1 passage
• Cardiovascular risks associated with use of non-steroidal anti-inflammatory drugs in patients with non-obstructive coronary artery disease.1 passage
• Cardiovascular safety of anti-diabetic drugs.1 passage
• Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.1 passage
• Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.1 passage
• Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome.1 passage
• Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.1 passage
• Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry.1 passage
• Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence.1 passage
• Circadian variation of ticagrelor-induced platelet inhibition in healthy adulty.1 passage
• Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial.1 passage
• Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).1 passage
• Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.1 passage
• Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.1 passage
• Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study.1 passage
• Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.1 passage
• Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries.1 passage
• Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.1 passage
• Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis.1 passage
• Concerns about the use of digoxin in acute coronary syndromes.1 passage
• Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study.1 passage
• Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations.1 passage
• Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).1 passage
• Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study.1 passage
• Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease.1 passage
• DOAC discontinuation among patients with atrial fibrillation according to gender and cohabitation status; A Nationwide Cohort Study.1 passage
• Danish trends in pharmacotherapy, comorbidities, and demographics in patients referred for coronary angiography: what changed during a decade?1 passage
• De-escalation of antiplatelets after percutaneous coronary intervention: a Bayesian network meta-analysis of various de-escalation strategies.1 passage
• Depressive symptoms and non-adherence to treatable cardiovascular risk factors' medications in the CONSTANCES cohort.1 passage
• Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients.1 passage
• Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations.1 passage
• Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes.1 passage
• Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy.1 passage
• Different left ventricular remodeling patterns and clinical outcomes between non-ischemic and ischemic etiologies in heart failure patients receiving sacubitril/valsartan treatment.1 passage
• Differential effects of dual antiplatelet therapy in patients presented with acute coronary syndrome vs. stable ischaemic heart disease after coronary artery bypass grafting.1 passage
• Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries.1 passage
• Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients.1 passage
• Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel.1 passage
• Drug therapy in cardiac arrest: a review of the literature.1 passage
• Dual antiplatelet therapy: optimal timing, management, and duration.1 passage
• Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network Meta-analysis.1 passage
• EFFECT oF STATIN THERAPY oN SARS-CoV-2 INFECTION-RELATED.1 passage
• ESC Council on hypertension position document on the management of hypertensive emergencies.1 passage
• ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry.1 passage
• Early glycaemic changes after initiation of oral antidiabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes.1 passage
• Early occurrence of drug intolerance as risk factor during follow-up in patients with acute coronary syndrome or coronary revascularization.1 passage
• Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?1 passage
• Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.1 passage
• Effect of Ticagrelor Monotherapy on Mortality After PCI: A Systematic Review and Meta-Analysis of Randomized Trials Including 26143 patients.1 passage
• Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial.1 passage
• Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction.1 passage
• Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies.1 passage
• Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis.1 passage
• Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease.1 passage
• Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort.1 passage
• Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy.1 passage
• Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.1 passage
• Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.1 passage
• Effectiveness of colchicine for the prevention of recurrent pericarditis and post-pericardiotomy syndrome: an updated meta-analysis of randomized clinical data.1 passage
• Effects of digitalis on mortality in a large cohort of implantable cardioverter defibrillator recipients: results of a long-term follow-up study in 1020 patients.1 passage
• Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.1 passage
• Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis.1 passage
• Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials.1 passage
• Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis.1 passage
• Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): a multicenter, randomized, double-blind, placebo-controlled trial.1 passage
• Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.1 passage
• Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients.1 passage
• Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.1 passage
• Epinephrine administration for adult out-of-hospital cardiac arrest patients with refractory shockable rhythm: time-dependent propensity score-sequential matching analysis from a nationwide population-based registry.1 passage
• Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.1 passage
• External applicability of the COMPASS trial: the Western Denmark Heart Registry.1 passage
• Fast versus ultra-slow thrombolytic infusion regimens in patients with obstructive mechanical prosthetic valve thrombosis: a pilot randomized clinical trial.1 passage
• From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.1 passage
• Gastrointestinal haemorrhage in atrial fibrillation patients: impact of quality of anticoagulation control.1 passage
• Gender differences in the effects of cardiovascular drugs.1 passage
• Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.1 passage
• Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction.1 passage
• Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with ACS: a meta-analysis.1 passage
• Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants.1 passage
• Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction.1 passage
• Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial.1 passage
• High burden of drug therapy in adult congenital heart disease: polypharmacy as marker of morbidity and mortality.1 passage
• How to implement the recommendations of the 2018 ESC/ESH Hypertension Guidelines in a given patient: a step by step approach.1 passage
• Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial.1 passage
• Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).1 passage
• Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database.1 passage
• Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease.1 passage
• Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial.1 passage
• Impact of angiotensin receptor blockers on mortality after hospitalization for symptomatic lower extremity artery disease.1 passage
• Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial.1 passage
• Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study.1 passage
• Impact of opioids on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.1 passage
• Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.1 passage
• Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting.1 passage
• Impact of vitamin D on cardiac structure and function in chronic kidney disease patients with hypovitaminosis D: a randomized controlled trial and meta-analysis.1 passage
• Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study.1 passage
• Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis.1 passage
• Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.1 passage
• Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes.1 passage
• Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial.1 passage
• Interleukin-1 blockade for the treatment of pericarditis.1 passage
• Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials.1 passage
• Iron deficiency in patients with heart failure.1 passage
• Is P2Y12 inhibitor therapy associated with an increased risk of cancer?1 passage
• Is the use of renin-angiotensin system inhibitors in patients with aortic valve stenosis safe and of prognostic benefit? A systematic review and meta-analysis.1 passage
• Left ventricular thrombosis: new perspectives on an old problem.1 passage
• Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.1 passage
• Long-term antiarrhythmic drug treatment after atrial fibrillation ablation: does a too obstinate rhythm control strategy bring serious risk of proarrhythmia to ablated patients?1 passage
• Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study.1 passage
• Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk.1 passage
• Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies.1 passage
• Loop diuretics for chronic heart failure: a foe in disguise of a friend?1 passage
• Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk-an inverse probability of treatment weighted study on 54 872 patients.1 passage
• Low quality of some generic cardiovascular medicinal products represents a matter for growing concern.1 passage
• Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial.1 passage
• Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report.1 passage
• Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).1 passage
• Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues.1 passage
• Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment elevation myocardial infarction.1 passage
• Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?1 passage
• Medication in adults after atrial switch for transposition of the great arteries: clinical practice and recommendations.1 passage
• Melatonin has multiorgan effects.1 passage
• Meta-analysis of admission hyperglycaemia in acute myocardial infarction patients treated with primary angioplasty: a cause or a marker of mortality?1 passage
• Meta-analysis of studies examining the external validity of the dual antiplatelet therapy score.1 passage
• Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation.1 passage
• Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?1 passage
• Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives.1 passage
• Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.1 passage
• Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System.1 passage
• Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomized clinical trial.1 passage
• NSAIDs are associated with increased risk of atrial fibrillation in patients with prior myocardial infarction: a nationwide study.1 passage
• Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge.1 passage
• New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF.1 passage
• New oral anticoagulants: a practical guide for physicians.1 passage
• New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.1 passage
• Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study.1 passage
• Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease.1 passage
• Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis.1 passage
• Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA).1 passage
• Obesity and atrial fibrillation: making inroads through fat.1 passage
• Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation.1 passage
• Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence.1 passage
• Optimal P2Y12 inhibition in older adults with acute coronary syndromes: A network meta-analysis of randomized controlled trials.1 passage
• Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival.1 passage
• Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.1 passage
• Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events.1 passage
• Outcomes after delayed primary percutaneous coronary intervention versus pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway.1 passage
• Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.1 passage
• Outcomes of digoxin vs. beta-blocker in AF: report from ESC-EHRA EORP-AF Long-Term General Registry.1 passage
• Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease.1 passage
• P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects.1 passage
• P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients.1 passage
• P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries.1 passage
• PCSK9 and inflammation: a review of experimental and clinical evidence.1 passage
• PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY.1 passage
• Patient-reported outcomes and medication adherence in patients with heart failure.1 passage
• Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trials.1 passage
• Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension.1 passage
• Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions.1 passage
• Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.1 passage
• Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model.1 passage
• Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.1 passage
• Pharmacotherapy for coronary microvascular dysfunction.1 passage
• Plaque imaging to refine indications for emerging lipid-lowering drugs.1 passage
• Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study.1 passage
• Potentially Inappropriate Prescriptions in Heart Failure with Reduced Ejection Fraction (PIP-HFrEF).1 passage
• Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention.1 passage
• Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study.1 passage
• Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters.1 passage
• Prescriber responsibility, predictors for initiation, and 20-year trends in use of non-aspirin non-steroidal anti-inflammatory drugs in patients with cardiovascular contraindications: a nationwide cohort study.1 passage
• Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.1 passage
• Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events.1 passage
• Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study.1 passage
• Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).1 passage
• Rationale, experimental data, and emerging clinical evidence on early and preventive use of levosimendan in patients with ventricular dysfunction.1 passage
• Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study.1 passage
• Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients.1 passage
• Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review.1 passage
• Recent developments in the science of proarrhythmic cardiac safety of new drugs.1 passage
• Recombinant human Lecithin-Cholesterol acyltransferase in patients with atherosclerosis: Phase 2a primary results and phase 2b design.1 passage
• Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VALIDATE-SWEDEHEART substudy.1 passage
• Renal protection in chronic heart failure: focus on sacubitril/valsartan.1 passage
• Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence.1 passage
• Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes fromCoViD-19: systematic review and meta-analysis.1 passage
• Resistant hypertension: new insights and therapeutic perspectives.1 passage
• Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.1 passage
• Response to the 'Comment on the editorial by Turner et al. on Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.'1 passage
• Risk factor changes and incident atrial fibrillation among middle-aged men in the Malmö Preventive Project cohort.1 passage
• Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists.1 passage
• Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.1 passage
• Risk of infections in patients treated with ticagrelor vs. clopidogrel: a systematic review and meta-analysis.1 passage
• Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.1 passage
• Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.1 passage
• Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.1 passage
• Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.1 passage
• Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.1 passage
• Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.1 passage
• Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction.1 passage
• Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial.1 passage
• Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects.1 passage
• Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.1 passage
• Statin but not Aspirin Treatment is Associated with Reduced Cardiovascular Risk in Patients with Diabetes without Obstructive Coronary Artery Disease.1 passage
• Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose.1 passage
• THE CARDIOVASCULAR EFFECTS OF GNRH ANTAGONISTS IN MEN WITH PROSTATE CANCER.1 passage
• Targeting T cells to treat atherosclerosis: odyssey from bench to bedside.1 passage
• Temporal trends in acute myocardial infarction presentation and association with use of cardioprotective drugs: a nationwide registry-based study.1 passage
• The Heart Failure Association Congress confirms itself as the largest European Society of Cardiology sub-speciality congress.1 passage
• The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.1 passage
• The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.1 passage
• The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials.1 passage
• The association of PRECISE-DAPT score with ischemic outcomes in patients taking dual antiplatelet therapy following percutaneous coronary intervention: a meta analysis.1 passage
• The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?1 passage
• The current role and future prospects of D-dimer biomarker.1 passage
• The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014.1 passage
• The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management.1 passage
• The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.1 passage
• The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF Registry.1 passage
• The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study.1 passage
• The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent.1 passage
• The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction.1 passage
• Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study.1 passage
• Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study.1 passage
• Ticagrelor and The Risk of Staphylococcus Aureus Bacteremia and Other Infections.1 passage
• Time to epinephrine and survival after paediatric out-of-hospital cardiac arrest.1 passage
• Time to treatment still matters in ST-elevation myocardial infarction: a call to maintain treatment effectiveness during the COVID-19 pandemic.1 passage
• Treating arrhythmias with adjunctive magnesium: identifying future research directions.1 passage
• Treatment of fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).1 passage
• Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.1 passage
• Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting.1 passage
• Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint.1 passage
• Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention.1 passage
• Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.1 passage
• Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries.1 passage
• Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.1 passage
• Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials.1 passage
• Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation.1 passage
• Weekend versus weekday admission and clinical outcomes in heart failure patients with and without atrial fibrillation in Taiwan.1 passage
• With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion.1 passage
• β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction.1 passage